Effect of cholecystokinin on lower oesophageal sphincter pressure and transient lower oesophageal sphincter relaxations in humans
- PMID: 7890233
- PMCID: PMC1382350
- DOI: 10.1136/gut.36.1.39
Effect of cholecystokinin on lower oesophageal sphincter pressure and transient lower oesophageal sphincter relaxations in humans
Abstract
The effect of cholecystokinin (CCK) on the lower oesophageal sphincter (LOS) pressure, frequency of transient LOS relaxations, and the number of reflux episodes was investigated in six healthy subjects. LOS pressure was recorded on four separate occasions during continuous intravenous infusion of either saline or CCK-33 in doses of 0.25, 0.5, or 1.0 Ivy Dog units per kg body weight per hour (IDU.kg-1.h-1) for 90 minutes. Plasma CCK concentrations did not change during saline infusion, but increased significantly from 2.5 (0.3) pmol/l to steady state levels of 4.0 (0.4) pmol/l, 6.1 (0.4) pmol/l, and 9.3 (0.9) pmol/l respectively starting from 30 minutes. LOS pressure did not change significantly during infusion of saline or of CCK-33 at doses of 0.25 or 0.5 IDU.kg-1.h-1. However, a significant (p < 0.05) reduction in LOS pressure to a minimum level of 12 (4) mm Hg at 30 minutes compared with basal level (18 (4) mm Hg) and compared with saline was observed during infusion of CCK-33 at a dose of 1.0 IDU.kg-1.h-1. In addition, oesophageal motility and pH were recorded simultaneously in these six subjects on two separate occasions one hour before (fasting) and three hours during administration of a gastric load (dextrose 5%, pH 3) combined with continuous intravenous infusion of saline or CCK-33 at a dose of 1.0 IDU,kg-1.h-1. Plasma CCK concentrations did not change during the gastric load combined with saline, but increased significantly to a steady state level of 10.8 (0.8) pmol/l during intravenous infusion of CCK. The number of transient LOS relaxations increased significantly in the first hour during administration of the gastric load compared with fasting levels, both during saline infusion (fasting: 1.7 (0.6)/h, 1st hour: 4.3 (1.2)/h) and during CCK infusion (fasting: 1.7 (0.5)/h, 1st hour: 3.8 (0.7)/h). In the second and third hours the number of transient LOS relaxations fell to fasting levels in both experiments. No significant differences were observed in the number and type of transient LOS relaxations, mechanism of gastro-oesophageal reflux, or duration of acid exposure between the two experiments. It is concluded that in healthy subjects infusion of CCK-33 in a dose of 1.0 IDU.kg-1.h-1 significantly reduces LOS pressure but does not affect the frequency of transient LOS relaxations or acid exposure time during a continuous liquid gastric load.
Comment in
-
Cholecystokinin and transient lower oesophageal sphincter relaxation.Gut. 1995 Aug;37(2):298. doi: 10.1136/gut.37.2.298-a. Gut. 1995. PMID: 7557591 Free PMC article. No abstract available.
Similar articles
-
Cholecystokinin in transient lower oesophageal sphincter relaxation due to gastric distension in humans.Gut. 1997 May;40(5):575-81. doi: 10.1136/gut.40.5.575. Gut. 1997. PMID: 9203932 Free PMC article. Clinical Trial.
-
Effect of atropine on gastro-oesophageal reflux and transient lower oesophageal sphincter relaxations in patients with gastro-oesophageal reflux disease.Gut. 1998 Jul;43(1):12-6. doi: 10.1136/gut.43.1.12. Gut. 1998. PMID: 9771399 Free PMC article. Clinical Trial.
-
The effect of cholecystokinin antagonism on postprandial lower oesophageal sphincter function in asymptomatic volunteers and patients with reflux disease.Aliment Pharmacol Ther. 2001 Sep;15(9):1357-64. doi: 10.1046/j.1365-2036.2001.01045.x. Aliment Pharmacol Ther. 2001. PMID: 11552906 Clinical Trial.
-
Transient lower oesophageal sphincter relaxations--a pharmacological target for gastro-oesophageal reflux disease?Aliment Pharmacol Ther. 2002 Jan;16(1):17-26. doi: 10.1046/j.1365-2036.2002.01153.x. Aliment Pharmacol Ther. 2002. PMID: 11856074 Review.
-
The anti-reflux barrier and mechanisms of gastro-oesophageal reflux.Baillieres Best Pract Res Clin Gastroenterol. 2000 Oct;14(5):681-99. doi: 10.1053/bega.2000.0118. Baillieres Best Pract Res Clin Gastroenterol. 2000. PMID: 11003803 Review.
Cited by
-
The Role of a Plant-Only (Vegan) Diet in Gastroesophageal Reflux Disease: Online Survey of the Italian General Population.Nutrients. 2023 Nov 8;15(22):4725. doi: 10.3390/nu15224725. Nutrients. 2023. PMID: 38004119 Free PMC article.
-
Risk factors of gastroesophageal reflux disease in Shiraz, southern Iran.World J Gastroenterol. 2007 Nov 7;13(41):5486-91. doi: 10.3748/wjg.v13.i41.5486. World J Gastroenterol. 2007. PMID: 17907293 Free PMC article.
-
Does impaired gallbladder function contribute to the development of Barrett's esophagus and esophageal adenocarcinoma?J Gastrointest Surg. 2011 Jun;15(6):908-14. doi: 10.1007/s11605-011-1520-z. Epub 2011 Apr 12. J Gastrointest Surg. 2011. PMID: 21484485
-
Cholecystokinin in transient lower oesophageal sphincter relaxation due to gastric distension in humans.Gut. 1997 May;40(5):575-81. doi: 10.1136/gut.40.5.575. Gut. 1997. PMID: 9203932 Free PMC article. Clinical Trial.
-
Cholelithiasis and cholecystectomy increase the risk of gastroesophageal reflux disease and Barrett's esophagus.Front Med (Lausanne). 2024 Jul 18;11:1420462. doi: 10.3389/fmed.2024.1420462. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39091288 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical